

National Cholesterol Education Program

Adult Treatment Panel III Report

2001

ATP III Outline

Acknowledgments	ix
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).....	ix
Executive Committee Advisor and Reviewers	ix
National Cholesterol Education Program Coordinating Committee	ix
I. Background and Introduction	I-1
1. Development of an evidence-based report.....	I-1
2. Features of ATP III similar to those of ATP I and II.....	I-2
3. New features of ATP III	I-3
4. Relation of ATP III to NCEP’s public health approach	I-4
5. Relation of ATP III to other clinical guidelines.....	I-5
II. Rationale for Intervention	II-1
1. Basic description of lipids and lipoproteins.....	II-1
2. LDL cholesterol as the primary target of therapy	II-1
a. Serum LDL cholesterol as a major cause of CHD.....	II-2
b. Serum LDL cholesterol as target of therapy	II-4
c. Categories and classification of total cholesterol and LDL cholesterol.....	II-7
3. Other lipid risk factors	II-8
a. Triglycerides	II-8
1) Elevated serum triglycerides (and triglyceride-rich lipoproteins) as a risk factor	II-8
2) Lipoprotein remnants as atherogenic lipoproteins.....	II-8
3) VLDL cholesterol as a marker for remnant lipoproteins.....	II-9
4) Causes of elevated serum triglyceride	II-9
5) Categories of serum triglycerides.....	II-9
6) Elevated serum triglycerides and triglyceride-rich lipoproteins as targets of therapy.....	II-10
b. Non-HDL cholesterol.....	II-11
1) Non-HDL cholesterol as a risk factor.....	II-11
2) Non-HDL cholesterol as a secondary target of therapy	II-12
c. High density lipoproteins (HDL)	II-13
1) Low HDL cholesterol as an independent risk factor for CHD	II-13
2) Causes of low HDL cholesterol.....	II-14
3) Classification of serum HDL cholesterol	II-15
4) Low HDL cholesterol as a potential target of therapy.....	II-16
d. Atherogenic dyslipidemia	II-16
1) Atherogenic dyslipidemia as a “risk factor”	II-16
2) Atherogenic dyslipidemia as a target of therapy	II-17
4. Nonlipid risk factors	II-22
a. Modifiable risk factors	II-23
1) Hypertension.....	II-23

2) Cigarette smoking.....	II-24
3) Diabetes	II-24
4) Overweight/obesity.....	II-25
5) Physical inactivity.....	II-26
6) Atherogenic diet	II-27
b. Nonmodifiable risk factors	II-28
1) Age.....	II-28
2) Male sex.....	II-28
3) Family history of premature CHD.....	II-29
5. Emerging risk factors.....	II-30
a. Emerging lipid risk factors.....	II-31
1) Triglycerides.....	II-31
2) Lipoprotein remnants.....	II-31
3) Lipoprotein (a).....	II-32
4) Small LDL particles.....	II-33
5) HDL subspecies.....	II-33
6) Apolipoproteins	II-33
a) Apolipoprotein B	II-33
b) Apolipoprotein AI.....	II-34
7) Total cholesterol/HDL-cholesterol ratio.....	II-34
b. Emerging nonlipid risk factors.....	II-34
1) Homocysteine	II-34
2) Thrombogenic/hemostatic factors	II-35
3) Inflammatory markers	II-36
4) Impaired fasting glucose.....	II-36
c. Subclinical atherosclerotic disease.....	II-37
1) Ankle-brachial blood pressure index (ABI)	II-37
2) Tests for myocardial ischemia.....	II-37
3) Tests for atherosclerotic plaque burden.....	II-38
a) Carotid intimal medial thickening	II-38
b) Coronary calcium	II-38
6. Metabolic syndrome.....	II-39
a. Metabolic syndrome as multiple, interrelated factors that raise risk	II-39
b. Diagnosis of metabolic syndrome.....	II-40
c. Metabolic syndrome as a target of therapy	II-41
7. Primary prevention: persons without established CHD.....	II-42
a. Scope of primary prevention.....	II-42
b. Clinical strategy in primary prevention effort	II-42
c. Concepts of short-term and long-term prevention	II-43
d. Role of LDL lowering in short-term and long-term primary prevention.....	II-43
e. Risk assessment in primary prevention.....	II-44
f. Primary prevention with lifestyle changes	II-46
1) Basis for lifestyle recommendations for primary prevention	II-46
2) Dietary clinical trials of cholesterol lowering	II-46
3) Linkage of public health approach and clinical approach in primary prevention.....	II-46
g. Effectiveness of LDL-lowering drugs in primary prevention.....	II-46

h.	Selection of persons for short-term risk reduction with LDL-lowering drugs	II-47
i.	Selection of older persons for short-term, primary prevention.....	II-48
j.	Selection of persons for long-term primary prevention in the clinical setting	II-49
k.	LDL goals in primary prevention	II-54
8.	Secondary prevention: persons with CHD.....	II-56
a.	Secondary prevention of recurrent CHD.....	II-56
b.	Effects of lipid-lowering therapy on stroke	II-62
9.	Total mortality considerations and therapeutic safety	II-62
10.	Magnitude of reduction in CHD risk	II-65
11.	CHD as a risk indicator.....	II-66
12.	Concept of CHD risk equivalents	II-67
a.	Other forms of clinical atherosclerotic disease	II-67
1)	Peripheral arterial disease (PAD)	II-67
2)	Carotid artery disease	II-70
3)	Abdominal aortic aneurysm (AAA)	II-73
b.	Diabetes as a CHD risk equivalent	II-74
c.	High-risk persons with multiple risk factors.....	II-78
13.	Models for clinical intervention: role of multidisciplinary team	II-79
14.	Cost-effectiveness issues	II-80
a.	Purpose of cost-effectiveness analysis of LDL-lowering therapy	II-80
b.	Approaches to estimating cost-effectiveness of cholesterol-lowering therapies	II-81
c.	Criteria for cost-effectiveness therapies.....	II-84
d.	Cost effectiveness analysis for LDL lowering for secondary prevention (persons with established CHD)	II-84
e.	Cost effectiveness analysis in persons with CHD risk equivalents.....	II-85
f.	Cost effectiveness of primary prevention.....	II-85
1)	Cost effectiveness of dietary therapy for primary prevention.....	II-85
2)	Cost effectiveness of drug therapy for short-term primary prevention	II-85
3)	Cost-effectiveness for primary prevention based on WOSCOPS results.....	II-86
4)	Cost effectiveness of primary prevention based on the AFCAPS/TexCAPS trial.....	II-86
5)	Cost-effectiveness in long-term primary prevention	II-87
g.	Summary	II-87

III. Detection and Evaluation III-1

1.	Identification of risk categories for setting of LDL-cholesterol goals.....	III-1
a.	Identification of persons with CHD and CHD risk equivalent	III-1
b.	Risk assessment in persons without CHD or CHD risk equivalents (starting with risk factor counting)	III-2
1)	Identification of persons with multiple (2+) risk factors.....	III-3
2)	Calculation of 10-year CHD risk.....	III-3
2.	Determination and classification of LDL cholesterol.....	III-8
a.	Who should be tested for cholesterol and lipoproteins?	III-8
b.	Procedures of measurement	III-9
c.	Classification of lipid and lipoprotein levels	III-10
d.	Secondary dyslipidemias (see Section VII).....	III-10

3. Atherogenic dyslipidemia and the metabolic syndrome	III-11
a. Atherogenic dyslipidemia and classification of serum triglycerides	III-11
b. Diagnosis of the metabolic syndrome.....	III-11
4. Role of emerging risk factors in risk assessment.....	III-11
IV. General Approach to Treatment—Goals and Thresholds	IV-1
1. Therapeutic goals for LDL cholesterol.....	IV-1
2. Management of LDL Cholesterol	IV-2
a. CHD and CHD risk equivalents.....	IV-2
1) Baseline LDL cholesterol \geq 130 mg/dL	IV-3
2) Baseline LDL cholesterol 100–129 mg/dL	IV-3
3) Baseline LDL cholesterol <100 mg/dL	IV-3
b. Multiple (2+) risk factors.....	IV-4
1) Multiple risk factors, 10-year risk >20 percent	IV-4
2) Multiple risk factors, 10-year risk 10–20 percent.....	IV-4
3) Multiple risk factors, 10-year risk <10 percent	IV-4
c. Zero to one risk factor.....	IV-5
d. Management of LDL cholesterol when risk assessment begins with Framingham scoring (Table IV.2–4)	IV-5
e. Recommendations for persons whose LDL cholesterol levels are below goal.....	IV-6
f. LDL-lowering therapy in older persons	IV-7
3. Management of atherogenic dyslipidemia and the metabolic syndrome.....	IV-7
a. Atherogenic dyslipidemia	IV-7
b. Metabolic syndrome.....	IV-7
V. Adopting Healthful Lifestyle Habits to Lower LDL Cholesterol and Reduce CHD Risk.....	V-1
1. Population approach: promoting a base of healthy life habits.....	V-1
2. General approach to therapeutic lifestyle changes (TLC)	V-5
3. Components of the TLC diet.....	V-13
a. Major nutrient components	V-13
1) Saturated fatty acids.....	V-13
2) Trans fatty acid	V-15
3) Dietary cholesterol.....	V-15
4) Monounsaturated fatty acids.....	V-16
5) Polyunsaturated fatty acids.....	V-17
6) Total fat.....	V-18
7) Carbohydrate	V-19
8) Protein.....	V-20
b. Additional dietary options for LDL lowering.....	V-20
1) Increasing viscous fiber in the diet.....	V-20
2) Plant stanols/sterols	V-21
3) Soy protein.....	V-22
c. Other dietary factors that may reduce baseline risk for CHD	V-22
1) n-3 (omega-3) polyunsaturated fatty acids	V-23
2) Vitamins/antioxidants.....	V-24
a) Folic acid and vitamins B6 and B12.....	V-24

b) Antioxidants.....	V-25
3) Moderate intakes of alcohol	V-26
4) Dietary sodium, potassium, and calcium.....	V-27
5) Herbal or botanical dietary supplements	V-28
6) High protein, high total fat and saturated fat weight loss regimens	V-28
4. Management of the metabolic syndrome through life habit changes	V-29
a. Weight control.....	V-29
b. Increased regular physical activity.....	V-30
5. Practical approach to life habit changes.....	V-30
a. Role of the physician.....	V-30
1) Visit 1: Risk assessment, diet assessment, and initiation of therapeutic lifestyle change	V-31
2) Visit 2: Intensifying the TLC diet for LDL cholesterol lowering	V-31
3) Visit 3: Decision about drug therapy; initiating management of the metabolic syndrome	V-32
4) Visit N: Long-term follow-up and monitoring adherence to therapeutic lifestyle changes (TLC).....	V-34
b. Role of nurses, physician assistants, and pharmacists	V-34
c. Specific role of registered dietitians and other qualified nutrition professionals....	V-35
1) Role of the nutrition professional in LDL-lowering therapy.....	V-35
a) First: dietary assessment	V-36
b) Dietary guidance on adopting the TLC Diet	V-36
c) Specific foods and preparation techniques	V-37
d) Recommendations by food group.....	V-38
e) Other eating tips.....	V-40
2) Role of the dietitian in management of the metabolic syndrome	V-41
6. Improving patient adherence to life habit changes	V-41

Diet Appendix A

Sample Dietary Assessment Questionnaire (Part 1) MEDFACTS*	A-1
Sample Dietary Assessment Questionnaire (Part 2) MEDFACTS*	A-2

Diet Appendix B

TLC Sample Menu—Traditional American Cuisine, Male, 25-49 Years	B-1
TLC Sample Menu—Traditional American Cuisine, Female, 25-49 Years.....	B-2
TLC Sample Menu—Lacto Ovo Vegetarian Cuisine, Male, 25-49 Years	B-3
TLC Sample Menu—Lacto Ovo Vegetarian Cuisine, Female, 25-49 Years.....	B-4
TLC Sample Menu—Southern Cuisine, Male, 25-49 Years	B-5
TLC Sample Menu—Southern Cuisine, Female, 25-49 Years	B-6
TLC Sample Menu—Asian Cuisine, Male, 25-49 Years.....	B-7
TLC Sample Menu—Asian Cuisine, Female, 25-49 Years	B-8
TLC Sample Menu—Mexican-American Cuisine, Male, 25-49 Years.....	B-9
TLC Sample Menu—Mexican-American Cuisine, Female, 25-49 Years	B-10

Diet Appendix C

Saturated Fat, Total Fat, Cholesterol, and Omega-3 Content of Meat, Fish, and Poultry in 3-Ounce Portions Cooked Without Added Fat	C-1
--	-----

VI. Drug Therapy	VI-1
1. Thresholds and goals for drug treatment	VI-1
a. Drug therapy to achieve treatment goals: overview.....	VI-1
b. Cholesterol management in persons with CHD or CHD risk equivalents.....	VI-3
1) Baseline LDL cholesterol \geq 130 mg/dL	VI-3
2) On-treatment LDL cholesterol 100–129 mg/dL.....	VI-3
3) Baseline LDL cholesterol 100–129 mg/dL	VI-4
4) Baseline LDL cholesterol <100 mg/dL	VI-5
5) Initiating cholesterol-lowering drugs in hospitalized patients.....	VI-5
6) Special considerations for drug therapy in CHD patients	VI-6
c. General principles of primary prevention with drug therapy	VI-7
d. Drug considerations for persons with multiple (2+) risk factors	VI-7
1) 10-year risk >20 percent.....	VI-7
2) 10-year risk 10–20 percent	VI-8
3) 10-year risk <10 percent.....	VI-8
e. Drug considerations for persons with 0–1 risk factor, 10-year risk <10 percent....	VI-8
2. Available drug therapies	VI-8
a. Overview and general approach.....	VI-8
b. Major drugs.....	VI-9
1) HMG CoA reductase inhibitors (statins)—lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin.....	VI-9
2) Bile acid sequestrants—cholestyramine, colestipol, colesevelam.....	VI-13
3) Nicotinic acid.....	VI-15
4) Fibric acid derivatives (fibrates): gemfibrozil, fenofibrate, clofibrate	VI-18
c. Other drugs.....	VI-22
d. n-3 fatty acids.....	VI-22
e. Hormone replacement therapy (HRT)	VI-23
1) Selective estrogen receptor modulators (SERM)—Raloxifene.....	VI-24
f. Miscellaneous drugs and therapeutic approaches.....	VI-25
1) Investigational drugs.....	VI-25
2) Other approaches	VI-25
3. Selection of drugs for elevated LDL cholesterol	VI-25
a. Practical advice on combined drug therapy	VI-27
1) Statin—bile acid sequestrant combination	VI-27
2) Statin—fibrate combination therapy	VI-28
3) Statin—nicotinic acid combination therapy	VI-30
4) Fibrate—nicotinic acid combination therapy	VI-30
4. Initiation, monitoring and followup of drug treatment	VI-30
a. Initiation of LDL-lowering drug therapy	VI-30
b. Baseline measurements.....	VI-31
c. Interval of follow up.....	VI-32
d. Followup treatment decisions	VI-33
VII. Management of Specific Dyslipidemias	VII-1
1. Very high LDL cholesterol	VII-1
a. Familial hypercholesterolemia (FH)	VII-3
b. Familial defective apolipoprotein B-100 (FDB).....	VII-4

c. Polygenic hypercholesterolemia	VII-4
2. Elevated triglycerides.....	VII-4
a. Classification, causation, and clinical significance.....	VII-4
1) Classification of serum triglycerides	VII-4
2) Causes of elevated triglycerides	VII-5
3) Relation of elevated triglycerides to CHD and other conditions.....	VII-7
b. Therapeutic considerations for persons with elevated triglycerides.....	VII-9
1) Non-HDL cholesterol: secondary target for persons with elevated triglycerides.....	VII-9
2) Changes in life habits are primary therapy for elevated triglycerides.....	VII-9
3) Special treatment considerations for different triglyceride categories (Table VII.2-4).....	VII-11
3. Low HDL cholesterol (without hypertriglyceridemia).....	VII-13
a. Definition, causes and relationship to CHD.....	VII-13
b. Therapeutic considerations in persons with low HDL cholesterol	VII-16
1) Clinical trial evidence.....	VII-16
2) Recommendations for low HDL cholesterol in persons with CHD or CHD risk equivalents, 10-year risk >20 percent	VII-17
3) Considerations for persons with low HDL cholesterol in other risk categories, 10-year risk \leq 20 percent.....	VII-17
4. Diabetic dyslipidemia	VII-18
a. Definition of diabetic dyslipidemia.....	VII-18
b. Role of elevated LDL and other risk factors in causation of CHD in persons with diabetes (Table VII.4-1).....	VII-19
c. Therapeutic recommendations for lipoprotein disorders in persons with diabetes	VII-21
1) Special therapeutic considerations according to LDL-cholesterol level (Table VII.4-2)	VII-21
2) Comments on specific drug classes used in management of lipid disorders in persons with diabetes	VII-23
5. Other secondary dyslipidemias.....	VII-24
6. Persons with high blood cholesterol and concomitant hypertension.....	VII-25
a. Therapeutic considerations.....	VII-25
b. Effects of antihypertensive agents on serum lipids.....	VII-26
c. Selection of antihypertensive therapy	VII-26
d. Selection of lipid-lowering therapy	VII-27
e. Compliance with therapy	VII-27
VIII. Special Considerations for Different Population Groups.....	VIII-1
1. Middle-aged men	VIII-1
2. Women.....	VIII-2
3. Older persons (men \geq 65 years; women \geq 75 years)	VIII-5
4. Younger adults (men 20-35 years; women 20-45 years).....	VIII-7
5. Racial and ethnic groups.....	VIII-8
a. African Americans	VIII-8
b. Hispanic Americans.....	VIII-11
c. Native Americans (American Indians).....	VIII-12

d. Asian and Pacific Islanders	VIII-13
e. South Asians	VIII-13
IX. Adherence.....	IX-1
1. Recurrent themes and perspectives	IX-2
2. Interventions to improve adherence.....	IX-3
a. Interventions focused on the patient	IX-3
1) Simplify medication regimens.....	IX-3
2) Provide explicit patient instruction and use good counseling techniques to teach the patient how to follow the prescribed treatment	IX-4
3) Encourage the use of prompts to help persons remember treatment regimens.....	IX-4
4) Use systems to reinforce adherence and maintain contact with the patient	IX-5
5) Encourage the support of family and friends.....	IX-5
6) Reinforce and reward adherence	IX-5
7) Increase patient visits for persons unable to achieve treatment goal.....	IX-6
8) Increase the convenience and access to care	IX-6
9) Involve patients in their care through self-monitoring	IX-6
b. Interventions focused on the physician and medical office	IX-6
1) Teach physicians to implement lipid treatment guidelines	IX-6
2) Use reminders to prompt physicians to attend to lipid management.....	IX-7
3) Identify a patient advocate in the office to help deliver or prompt care.....	IX-7
4) Use patients to prompt preventive care	IX-7
5) Develop a standardized treatment plan to structure care.....	IX-7
6) Use feedback from past performance to foster change in future care	IX-8
7) Remind patients of appointments and follow-up missed appointments	IX-8
c. Interventions focused on the health delivery system	IX-8
1) Provide lipid management through a lipid clinic.....	IX-8
2) Utilize case management by nurses.....	IX-9
3) Deploy telemedicine.....	IX-9
4) Utilize the collaborative care of pharmacists	IX-10
5) Execute critical care pathways in hospitals	IX-10
List of Studies	Studies-1
ATP III References	Ref-1

Acknowledgments

National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Members: Scott M. Grundy, M.D., Ph.D. (Chair of the panel), Diane Becker, R.N., M.P.H., Sc.D., Luther T. Clark, M.D., Richard S. Cooper, M.D., Margo A. Denke, M.D., Wm. James Howard, M.D., Donald B. Hunninghake, M.D., D. Roger Illingworth, M.D., Ph.D., Russell V. Luepker, M.D., M.S., Patrick McBride, M.D., M.P.H., James M. McKenney, Pharm.D., Richard C. Pasternak, M.D., F.A.C.C., Neil J. Stone, M.D., Linda Van Horn, Ph.D., R.D.

Ex-officio Members: H. Bryan Brewer, Jr., M.D., James I. Cleeman, M.D. (Executive Director of the panel), Nancy D. Ernst, Ph.D., R.D., David Gordon, M.D., Ph.D., Daniel Levy, M.D., Basil Rifkind, M.D., Jacques E. Rossouw, M.D., Peter Savage, M.D.

Consultants: Steven M. Haffner, M.D., David G. Orloff, M.D., Michael A. Proschan, Ph.D., J. Sanford Schwartz, M.D., Christopher T. Sempos, Ph.D.

Staff: Susan T. Shero, R.N., M.S., Elaine Z. Murray, Susan A. Keller, B.S.N., M.S.

Manuscript Preparation: Angela J. Jehle

Executive Committee Advisor and Reviewers

Executive Committee Advisor to the Panel: Stephen Havas, M.D., M.P.H., M.S.

Reviewers: Eugene Braunwald, M.D., W. Virgil Brown, M.D., Alan Chait, M.D., James E. Dalen, M.D., Valentin Fuster, M.D., Ph.D., Henry N. Ginsberg, M.D., Antonio M. Gotto, M.D., D.Phil., Ronald M. Krauss, M.D., John C. LaRosa, M.D., F.A.C.P., Thomas H. Lee, Jr., M.D., Linda Meyers, Ph.D., Michael Newman, M.D., Thomas Pearson, M.D., Ph.D., Daniel J. Rader, M.D., Frank M. Sacks, M.D., Ernst J. Schaefer, M.D., Sheldon G. Sheps, M.D., Lynn A. Smaha, M.D., Ph.D., Sidney C. Smith, Jr., M.D., Jeremiah Stamler, M.D., Daniel Steinberg, M.D., Ph.D., Nanette K. Wenger, M.D.

National Cholesterol Education Program Coordinating Committee

The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults was approved by the National Cholesterol Education Program Coordinating Committee, which comprises the following organizational representatives:

Member Organizations. National Heart, Lung, and Blood Institute – Claude Lenfant, M.D., (Chair), James I. Cleeman, M.D. (Coordinator), American Academy of Family Physicians – Theodore G. Ganiats, M.D., American Academy of Insurance Medicine – Gary Graham, M.D., American Academy of Pediatrics – Ronald E. Kleinman, M.D., American Association of Occupational Health Nurses – Pamela Hixon, B.S.N., R.N., C.O.H.N-S, American College of Cardiology – Richard C. Pasternak, M.D., F.A.C.C., American College of Chest Physicians – Gerald T. Gau, M.D., American College of Nutrition – Harry Preuss, M.D., American College of

Obstetricians and Gynecologists – Thomas C. Peng, M.D., American College of Occupational and Environmental Medicine – Ruth Ann Jordan, M.D., American College of Preventive Medicine – Lewis H. Kuller, M.D., Dr.P.H., American Diabetes Association, Inc. – Alan J. Garber, M.D., Ph.D., American Dietetic Association – Linda Van Horn, Ph.D., R.D., American Heart Association – Scott M. Grundy, M.D., Ph.D., American Hospital Association – Sandra Cornett, R.N., Ph.D., American Medical Association – Yank D. Coble, Jr., M.D., American Nurses Association, American Osteopathic Association – Michael Clearfield, D.O., American Pharmaceutical Association – James M. McKenney, Pharm.D., American Public Health Association – Stephen Havas, M.D., M.P.H., M.S., American Red Cross – Donald Vardell, M.S., Association of Black Cardiologists – Karol Watson, M.D., Ph.D., Association of State and Territorial Health Officials – Joanne Mitten, M.H.E., Citizens for Public Action on Blood Pressure and Cholesterol, Inc. – Gerald J. Wilson, M.A., M.B.A., National Black Nurses Association, Inc. – Linda Burnes-Bolton, Dr.P.H., R.N., M.S.N., F.A.A.N., National Medical Association – Luther T. Clark, M.D., Society for Nutrition Education – Darlene Lansing, M.P.H., R.D., Society for Public Health Education – Donald O. Fedder, Dr.P.H., M.P.H.

Associate Member Organization. American Association of Office Nurses – Joyce Logan.

Federal Agencies. NHLBI Ad Hoc Committee on Minority Populations – Yvonne L. Bronner, Sc.D., R.D., L.D., Agency for Healthcare Research and Quality – Francis D. Chesley, Jr., M.D., Centers for Disease Control and Prevention – Wayne Giles, M.D., M.P.H., Coordinating Committee for the Community Demonstration Studies – Thomas M. Lasater, Ph.D., Department of Agriculture – Alanna Moshfegh, M.S., R.D., Department of Defense – Col. Robert Dana Bradshaw, M.D., M.P.H., Food and Drug Administration – Elizabeth Yetley, Ph.D., Health Resources and Services Administration – Celia Hayes, M.P.H., R.D., National Cancer Institute – Carolyn Clifford, Ph.D., National Center for Health Statistics – Clifford Johnson, M.P.H., Office of Disease Prevention and Health Promotion – Elizabeth Castro, Ph.D., Department of Veterans Affairs – Pamela Steele, M.D.